-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
PRCT:NSD- (USD)
COMMON STOCK | Medical Devices |
Last Closing
USD 58.09Change
-0.71 (-1.21)%Market Cap
USD 3.54BVolume
0.35MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Medical Devices |
Last Closing
USD 58.09Change
-0.71 (-1.21)%Market Cap
USD 3.54BVolume
0.35MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
DXCM | DexCom Inc |
N/A |
USD 46.18B |
ALGN | Align Technology Inc |
N/A |
USD 17.85B |
PODD | Insulet Corporation |
N/A |
USD 13.96B |
BRKR | Bruker Corporation |
N/A |
USD 10.11B |
MASI | Masimo Corporation |
N/A |
USD 7.22B |
TMDX | TransMedics Group Inc |
N/A |
USD 4.74B |
AXNX | Axonics Modulation Technologie.. |
N/A |
USD 3.45B |
IRTC | iRhythm Technologies Inc |
N/A |
USD 3.09B |
LIVN | LivaNova PLC |
N/A |
USD 2.93B |
TNDM | Tandem Diabetes Care Inc |
N/A |
USD 2.78B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
W311:XETRA | HAN-GINS Indxx Healthcare.. | 1.66 % | 0.00 % |
N/A |
USD 0.02B |
WELL:PA | HAN-GINS Indxx Healthcare.. | 1.66 % | 0.00 % |
N/A |
N/A |
WELL:SW | HAN-GINS Indxx Healthcare.. | 1.66 % | 0.00 % |
N/A |
N/A |
WELP:LSE | HAN-GINS Indxx Healthcare.. | 1.47 % | 0.00 % |
N/A |
USD 0.02B |
FFTY | Innovator IBD® 50 ETF | 0.00 % | 0.80 % |
N/A |
USD 0.09B |
FYC | First Trust Small Cap Gro.. | 0.00 % | 0.70 % |
N/A |
USD 0.27B |
FYX | First Trust Small Cap Cor.. | 0.00 % | 0.63 % |
N/A |
USD 0.83B |
XHE | SPDR® S&P Health Care Eq.. | 0.00 % | 0.35 % |
N/A |
USD 0.25B |
WELL:LSE | Hanetf Icav - Han-Gins He.. | 0.00 % | 0.00 % |
N/A |
USD 0.02B |
DTEC | ALPS Disruptive Technolog.. | 0.00 % | 0.00 % |
N/A |
USD 0.10B |
W311:F | HAN-GINS Indxx Healthcare.. | 0.00 % | 0.00 % |
N/A |
USD 0.02B |
Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 38.61% | 88% | B+ | 90% | A- | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 38.61% | 88% | B+ | 90% | A- | ||
Trailing 12 Months | |||||||
Capital Gain | 66.73% | 92% | A | 93% | A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | 66.73% | 92% | A | 93% | A | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 13.39% | 64% | D | 72% | C | ||
Dividend Return | 13.39% | 64% | D | 71% | C- | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 35.54% | 82% | B | 52% | F | ||
Risk Adjusted Return | 37.66% | 88% | B+ | 70% | C- | ||
Market Capitalization | 3.54B | 94% | A | 86% | B+ |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median earnings growth in the previous 5 years compared to its sector